

Premature Ending (Study Not Started) of Study INZ701-201 in France

Inozyme Pharma, Inc filed the initial clinical trial application (CTA) in France on 26 April 2021. The initial CTA was approved on 7 June 2021. The Sponsor requested to withdraw the CTA in France on 7 October 2022. The rationale for requesting this withdrawal was due to the planned site ultimately being unable to participate in the clinical trial. The Sponsor opened the clinical trial in USA and UK and were able to complete enrollment using those countries. The study ran for 2.25 years and was completed on 9 July 2024. No patients were ever enrolled or treated in the study.